Treatment of atopic dermatitis
- Authors
- Han T.-Y.; Na C.H.; Lee J.H.; Kim H.O.; Park C.O.; Seo Y.J.; Son S.W.; Shin M.K.; Ahn J.Y.; Lee Y.W.; Jang Y.H.; Park Y.L.; Lew B.L.
- Issue Date
- 2018
- Publisher
- Korean Dermatological Association
- Keywords
- Atopic dermatitis; Guideline; Treatment
- Citation
- Korean Journal of Dermatology, v.56, no.10, pp 581 - 593
- Pages
- 13
- Indexed
- SCOPUS
KCI
- Journal Title
- Korean Journal of Dermatology
- Volume
- 56
- Number
- 10
- Start Page
- 581
- End Page
- 593
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/29227
- ISSN
- 0494-4739
- Abstract
- Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects both children and adults. AD is the cause of considerable morbidity including severe pruritus and impaired quality of life. Treatments for active disease include avoidance of triggering factors, barrier repair, topical medications including topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs), phototherapy, antibacterial agents, and systemic immunosuppressants including cyclosporine. Until recently, the only Food and Drug Administration (FDA)-approved systemic treatment options for patients with moderate-to-severe AD were steroids and cyclosporine. Systemic steroids are not recommended by current guidelines and are commonly associated with disease rebound. Instead, clinicians choose from several off-label immunosuppressants. In 2018, the Korean FDA approved dupilumab for adults with moderate-to-severe AD whose disease is not adequately controlled with topical therapies. The implementation of treatment guidelines for AD is challenging. Herein, we review the several treatment modalities for AD and recommend a treatment algorithm. © 2018 GSK group of companies or its licensor.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Dermatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.